查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1541129

2024-2032 年按疫苗类型、产品类型、配销通路（分销合作伙伴公司、非政府组织、政府机构）、最终用户和地区分類的肺炎球菌疫苗市场报告

Pneumococcal Vaccine Market Report by Vaccine Type, Product Type, Distribution Channel (Distribution Partner Companies, Non-Governmental Organizations, Government Authorities), End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3个工作天内

价格

2023年全球肺炎链球菌疫苗IMARC Group规模达94亿美元。市场的驱动因素包括败血症和肺炎疾病的增加、人口老化、医疗保健支出的增加、管理机构的倡议和资金、监管支持和批准、公共卫生运动以及疫苗技术的进步。

肺炎链球菌疫苗市场分析：

主要市场驱动因素：目标疾病数量的增加以及全球管理机构的措施正在促进市场成长。

主要市场趋势：研发（R＆D）活动投资的增加和肺炎疾病数量的增加正在对市场产生积极影响。

地理趋势：由于强大的医疗基础设施和持续的技术创新，北美占据了最大的市场份额。

竞争格局：肺炎链球菌疫苗产业的一些主要市场参与者包括 Astellas Pharma Inc.、GlaxoSmithKline Plc.、Merck & Co. Inc.、Panacea Biotec Ltd.、Pfizer Inc.、Sanofi SA、Serum Institute of India Pvt Ltd 和沃森生物科技有限公司等。

挑战与机会：虽然市场面临与疫苗相关的医疗问题等影响市场的挑战，但在新型疫苗的开发和批准方面也遇到了机会。

肺炎链球菌疫苗市场成长因素：

医疗保健支出不断增加

高医疗保健支出使政府和私人医疗保健部门能够在疫苗接种计划上投入更多资金，从而提高肺炎球菌疫苗的可及性和成本效益，从而提高人群的疫苗接种覆盖率。与此一致，增加医疗保健支出通常会转化为更好的医疗保健基础设施，包括疫苗接种诊所、分销网络和训练有素的医疗保健专业人员。该基础设施有助于肺炎球菌疫苗的管理和宣传，从而促进市场的成长。此外，高医疗保健支出可能会导致製药公司增加对研发（R&D）活动的​​投资，从而鼓励改进效果更好、覆盖更多血清型或需要更少剂量的肺炎球菌疫苗。根据美国医疗保险和医疗补助服务中心网站2024年更新的内容，预计医疗支出将占GDP的比重将从2022年的17.3%增加到2032年的19.7%。

人口老化加剧

由于免疫系统减弱和潜在的健康状况，老年人更容易患肺炎球菌感染，包括肺炎或侵袭性肺炎球菌疾病。这种日益增加的脆弱性导致人们高度利用肺炎球菌疫苗来避免此类严重疾病。除此之外，许多管理机构和医疗机构建议将老年人肺炎球菌疫苗接种作为常规免疫计划的一部分，这鼓励医疗保健提供者和老年人优先接种疫苗，从而推动肺炎球菌疫苗的需求。此外，医疗保健部门优先考虑针对老龄化人口的预防性护理策略，以改善他们的健康并最大限度地减少再入院率。世界卫生组织（WHO）网站上发表的一篇文章显示，到2050年，全球60岁以上的人口预计将增加一倍，达到近21亿。

败血症盛行率增加

根据世界卫生组织（WHO）网站2024年更新的内容，全球估计脓毒症病例中近2000万例发生在5岁以下儿童身上。引起肺炎球菌感染的肺炎链球菌是败血症的主要原因之一，特别是在免疫系统较弱的儿童。肺炎链球菌感染引起的败血症发生率不断上升，凸显了疫苗接种等预防措施的重要性。此外，接种肺炎链球菌疫苗可显着降低肺炎球菌感染的风险，包括那些可能导致败血症的风险。透过预防肺炎球菌疾病，疫苗有助于减轻医疗机构败血症的整体负担。除此之外，它们还透过预防肺炎球菌疾病来减轻护理机构败血症的整体负担。此外，肺炎球菌疫苗作为预防败血症的保护策略正在增加其销售量。透过全球公共卫生干预中的疫苗接种来预防败血症发病率和死亡率正在支持市场成长。

肺炎链球菌疫苗市场细分：

IMARC Group提供了每个细分市场的肺炎球菌疫苗产业趋势分析，以及 2024-2032 年全球、区域和国家层面的预测。我们的报告根据疫苗类型、产品类型、配销通路和最终用户对市场进行了分类。

依疫苗类型细分：

肺炎链球菌结合疫苗

肺炎链球菌多醣体疫苗

肺炎链球菌结合疫苗占据大部分市场份额

该报告根据疫苗类型对市场进行了详细的细分和分析。这包括肺炎链球菌结合疫苗和肺炎链球菌多醣体疫苗。根据该报告，肺炎链球菌结合疫苗占据了最大的份额。

肺炎链球菌结合疫苗 (PCV) 是市场上最重要的产品之一，因为它可以有效改善公众健康，特别是五岁以下儿童和老年人的健康。 PCV 旨在提供各种血清型肺炎链球菌的保护，已知这种细菌会导致严重甚至有时致命的疾病，例如肺炎、脑膜炎和败血症。 PCV已被证明可以有效降低这些疾病的发生率，这使得将其纳入国家免疫规划成为可能。

按产品类型划分：

普雷夫纳尔 13

合成花

肺炎疫苗23

Prevnar 13 占据业界第一份额

报告还根据产品类型对市场进行了详细的细分和分析。其中包括 Prevnar 13、synflorix 和 pneumovax 23。

Prevnar 13 因其可有效预防肺炎链球菌引起的感染而备受青睐。这种疫苗因其广泛覆盖 13 种不同的细菌菌株而特别引人注目。将其纳入世界各地的国家免疫计划极大地影响了肺炎球菌疾病的病例，尤其是幼儿和老年人。此外，其良好的临床有效性和安全性确保了其在世界各地的广泛使用，使其成为现代医疗保健系统对抗肺炎球菌疾病的重要支柱。

按配销通路划分：

分销合作伙伴公司

非政府组织 (NGO)

政府机关

非政府组织 (NGO) 代表了主要的细分市场

该报告根据配销通路对市场进行了详细的细分和分析。这包括分销合作伙伴公司、非政府组织 (NGO) 和政府当局。根据该报告，非政府组织（NGO）占最大部分。

非政府组织(NGO) 透过各种措施为市场动态做出贡献，包括为疫苗接种计划提供资金支持、提高对肺炎球菌免疫重要性的认识，以及与政府和製药公司合作确保疫苗的可负担性和可用性。非政府组织也参与研发活动，以提高疫苗效力并促进针对儿童和老年人等弱势群体的疫苗接种活动。他们的宣传工作也解决了医疗保健取得方面的社会经济差异，使肺炎球菌疫苗在全球范围内更容易获得和产生影响。

按最终用户划分：

儿科

成年人

报告还提供了基于最终用户的详细市场细分和分析。这包括儿科和成人。

儿童，尤其是婴儿和幼儿，非常容易受到肺炎球菌感染，这可能导致严重的疾病，例如肺炎、脑膜炎和败血症。因此，建议将肺炎链球菌疫苗接种作为全球儿童常规免疫计划的一部分。肺炎链球菌疫苗在预防这些感染方面的有效性正在显着降低全球儿童的发病率和死亡率。此外，针对儿科族群的公共卫生措施和免疫计画正在为肺炎球菌疫苗市场统计做出贡献。

随着成年人的衰老，尤其是 65 岁以上或有潜在健康问题的成年人，他们变得更容易受到肺炎球菌感染，这可能导致严重的疾病，如肺炎、脑膜炎和败血症。成人疫苗接种有助于降低这些感染及其相关併发症的风险，改善整体健康并降低医疗费用。此外，成年人通常是肺炎球菌的携带者，有可能将其传播给儿童和老年人等更脆弱的人。

按地区划分：

北美洲

美国

加拿大

亚太

中国

日本

印度

韩国

澳洲

印尼

其他的

欧洲

德国

法国

英国

义大利

西班牙

俄罗斯

其他的

拉丁美洲

巴西

墨西哥

其他的

中东和非洲

北美市场领先，占据最大的肺炎球菌疫苗市场份额

该报告还对所有主要区域市场进行了全面分析，其中包括北美（美国和加拿大）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告称，北美是肺炎链球菌疫苗最大的区域市场。

根据医疗保险和医疗补助服务中心网站 2023 年更新的内容，2022 年美国医疗保健支出成长 4.1%，达到 4.5 兆美元，即人均 13,493 美元。医疗保健支出的增加反映出人们更加重视透过创新技术改善患者的治疗结果并降低整体医疗保健成本。此外，北美拥有严格的监管框架和政府对免疫计划的大力支持，这对市场的成长做出了重大贡献。北美肺炎球菌疾病的流行，加上医疗保健专业人员和一般民众对疫苗接种益处的认识不断提高，也推动了对肺炎球菌疫苗的需求。

竞争格局：

市场肺炎球菌疫苗市场研究报告也对市场竞争格局进行了全面分析。也提供了所有主要公司的详细资料。肺炎链球菌疫苗产业的一些主要市场参与者包括 Astellas Pharma Inc.、GlaxoSmithKline Plc.、Merck & Co. Inc.、Panacea Biotec Ltd.、Pfizer Inc.、Sanofi SA、Serum Institute of India Pvt Ltd 和 Walvax Biotechnology有限公司

（请注意，这只是关键参与者的部分列表，报告中提供了完整列表。）

主要参与者正在投资旨在开发下一代疫苗配方的研发（R&D）活动。他们也正在扩大製造能力，以满足不断增长的全球需求。主要参与者也投资于临床试验和研究，以证明有效性和安全性。他们也采用创新技术进行疫苗生产和分配。许多公司正在实施疫苗接种活动和教育计划，以提高意识和疫苗接种率。主要参与者正在与其他行业利益相关者、政府机构、医疗保健组织和研究机构合作，扩大市场范围并开发新产品。例如，2023 年，Vaxcyte, Inc. 与 Lonza 合作达成了一项新的商业製造协议。透过此次合作，Vaxcyte 计划扩大其 PCV 候选药物的商业生产能力。

肺炎链球菌疫苗市场最新消息：

2024 年 1 月 26 日：辉瑞的 20 价肺炎链球菌结合疫苗候选药物 (20vPnC) 获得欧洲药品管理局 (EMA) 人用药品委员会 (CHMP) 的营销授权。

2024 年 4 月 22 日：武田、安斯泰来和三井住友银行宣布达成协议，成立合资公司，孵化早期药物发现计画。

本报告回答的关键问题

  • 2023年全球肺炎链球菌疫苗市场规模是多少
  • 2024-2032年全球肺炎链球菌疫苗市场的预期成长率是多少
  • COVID-19 对全球肺炎链球菌疫苗市场有何影响
  • 推动全球肺炎链球菌疫苗市场的关键因素是什么
  • 根据疫苗类型，全球肺炎链球菌疫苗市场的细分如何
  • 根据产品类型，全球肺炎链球菌疫苗市场的细分如何
  • 从配销通路来看，全球肺炎链球菌疫苗市场的细分如何
  • 全球肺炎链球菌疫苗市场的重点区域有哪些
  • 谁是全球肺炎链球菌疫苗市场的主要参与者/公司

本报告回答的关键问题

  • 2023年全球肺炎链球菌疫苗市场规模有多大？ 2024-2032年全球肺炎链球菌疫苗市场的预期成长率是多少？
  • COVID-19 对全球肺炎链球菌疫苗市场有何影响？
  • 推动全球肺炎链球菌疫苗市场的关键因素是什么？
  • 根据疫苗类型，全球肺炎链球菌疫苗市场的分布如何？
  • 根据产品类型，全球肺炎链球菌疫苗市场的细分如何？
  • 根据配销通路，全球肺炎链球菌疫苗市场的细分如何？
  • 全球肺炎链球菌疫苗市场的重点区域有哪些？
  • 全球肺炎链球菌疫苗市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球肺炎链球菌疫苗市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依疫苗类型

  • 肺炎链球菌结合疫苗
    • 市场趋势
    • 市场预测
  • 肺炎链球菌多醣体疫苗
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：依产品类型

  • 普雷夫纳尔 13
    • 市场趋势
    • 市场预测
  • 合成花
    • 市场趋势
    • 市场预测
  • 肺炎疫苗23
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：按配销通路

  • 分销合作伙伴公司
    • 市场趋势
    • 市场预测
  • 非政府组织 (NGO)
    • 市场趋势
    • 市场预测
  • 政府机关
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按最终用户

  • 儿科
    • 市场趋势
    • 市场预测
  • 成年人
    • 市场趋势
    • 市场预测

第 10 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第15章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Astellas Pharma Inc.
    • GlaxoSmithKline Plc.
    • Merck & Co. Inc.
    • Panacea Biotec Ltd.
    • Pfizer Inc.
    • Sanofi SA
    • Serum Institute of India Pvt Ltd.
    • Walvax Biotechnology Co. Ltd.
Product Code: SR112024A3133

The global pneumococcal vaccine market size reached US$ 9.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 14.4 Billion by 2032, exhibiting a growth rate (CAGR) of 4.7% during 2024-2032. The market is driven by the growing occurrence of sepsis and pneumonia diseases, rising aging population, increasing healthcare spending, governing agencies initiatives and funding, regulatory support and approvals, public health campaigns, and advancements in vaccine technology.

Pneumococcal Vaccine Market Analysis:

Major Market Drivers: The rise in the number of target diseases, along with governing agencies initiatives worldwide, is facilitating the market growth.

Key Market Trends: The growing investments in research and development (R&D) activities and increasing number of pneumonia diseases are positively influencing the market.

Geographical Trends: North America holds the largest segment because of strong healthcare infrastructure and ongoing innovations in technology.

Competitive Landscape: Some of the major market players in the pneumococcal vaccine industry include Astellas Pharma Inc., GlaxoSmithKline Plc., Merck & Co. Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt Ltd and Walvax Biotechnology Co. Ltd., among many others.

Challenges and Opportunities: While the market faces challenges like medical concerns associated with the vaccine, which impacts the market, it also encounters opportunities in the development and approval of novel vaccines.

Pneumococcal Vaccine Market Growth Factors:

Rising healthcare spending

High healthcare spending allows governments and private healthcare sectors to invest more in vaccination programs, leading to enhanced access and cost-effectiveness of pneumococcal vaccines, thereby increasing vaccination coverage rates across populations. In line with this, increasing healthcare spending often translates into better healthcare infrastructure, including vaccination clinics, distribution networks, and trained healthcare professionals. This infrastructure aids in the management and advocacy for pneumococcal vaccines, thus contributing to the growth of the market. Furthermore, high healthcare spending can lead to an increasing investment in research and development (R&D) activities by pharmaceutical companies, which encourages the enhancement of pneumococcal vaccines that work better, cover more serotypes or need fewer doses. According to the content updated in 2024 on the website of the Centers for Medicare & Medicaid Services, the health spending share of GDP is forecasted to grow from 17.3 percent in 2022 to 19.7 percent in 2032.

Growing aging population

Older people are more prone to pneumococcal infections, including pneumonia or invasive pneumococcal disease, due to weakened immune systems and underlying health conditions. This increasing vulnerability is leading to high utilization of pneumococcal vaccines to avoid such severe illnesses. Besides this, many governing agencies and healthcare organizations recommend pneumococcal vaccination for elderly populations as part of routine immunization schedules, which encourages healthcare providers and older adults to prioritize vaccination, thereby driving the pneumococcal vaccine demand. In addition, healthcare sectors prioritize preventive care strategies for aging populations to improve their health and minimize hospital readmissions. An article published on the website of the World Health Organization (WHO) shows that individuals aged over 60 are expected to double by 2050, reaching nearly 2.1 billion worldwide.

Increasing prevalence of sepsis

As per the content updated in 2024 on the website of the World Health Organization (WHO), almost 20 million of all estimated sepsis cases worldwide occurred in children under 5 years of age. Streptococcus pneumoniae, which causes pneumococcal infections, is one of the leading causes of sepsis, especially among children those with weakened immune systems. The rising occurrence of sepsis caused by pneumococcal infections underlines the importance of preventive approaches such as vaccination. In addition, vaccination against Streptococcus pneumoniae significantly reduces the risk of pneumococcal infections, including those that can lead to sepsis. By preventing pneumococcal diseases, vaccines help mitigate the overall burden of sepsis in healthcare settings. Apart from this, they reduce the overall burden of sepsis in care settings by preventing pneumococcal diseases. Furthermore, the administration of pneumococcal vaccines as a protective strategy against sepsis is increasing their sales. Prevention of sepsis morbidity and mortality through vaccination in public health intervention across the globe is supporting the market growth.

Pneumococcal Vaccine Market Segmentation:

IMARC Group provides an analysis of the pneumococcal vaccine industry trends in each segment, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on vaccine type, product type, distribution channel, and end user.

Breakup by Vaccine Type:

Pneumococcal Conjugate Vaccine

Pneumococcal Polysaccharide Vaccine

Pneumococcal conjugate vaccine accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the vaccine type. This includes pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine. According to the report, pneumococcal conjugate vaccine represents the largest segment.

The pneumococcal conjugate vaccine (PCV) is one of the most important products in the market because of its effectiveness in improving public health particularly among children below five years and elderly people. PCVs are aimed at offering protection against various serotypes of the streptococcus pneumoniae bacterium, which is known to cause severe and sometimes fatal conditions such as pneumonia, meningitis, and sepsis. PCVs have been proven to be effective in reducing the incidence of these diseases, which makes it possible to be incorporated in national immunization programs.

Breakup by Product Type:

Prevnar 13

Synflorix

Pneumovax 23

Prevnar 13 holds the largest share of the industry

A detailed breakup and analysis of the market based on the product type have also been provided in the report. This includes Prevnar 13, synflorix, and pneumovax 23. According to the report, Prevnar 13 accounts for the largest market share.

Prevnar 13 is highly preferable due to its effectiveness in preventing infections caused by Streptococcus pneumoniae bacteria. This vaccine is particularly notable for its broad coverage against thirteen different strains of the bacteria. Its incorporation in national immunization programs worldwide is greatly impacting the cases of pneumococcal diseases especially in young children and older individuals. Moreover, its well-established clinical effectiveness and safety profile are ensuring its escalated utilization throughout the world, making it an essential pillar of modern healthcare systems in combating pneumococcal diseases.

Breakup by Distribution Channel:

Distribution Partner Companies

Non-Governmental Organizations (NGO)

Government Authorities

Non-governmental organizations (NGO) represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes distribution partner companies, non-governmental organizations (NGO), and government authorities. According to the report, non-governmental organizations (NGO) represent the largest segment.

Non-governmental organizations (NGO) contribute to market dynamics through various initiatives, including funding support for vaccination programs, raising awareness about the importance of pneumococcal immunization, and collaborating with governments and pharmaceutical companies to ensure affordability and availability of vaccines. NGOs also engage in R&D activities to improve vaccine efficacy and promote vaccination campaigns aimed at vulnerable populations such as children and the elderly. Their advocacy efforts also address socio-economic disparities in healthcare access, making pneumococcal vaccines more accessible and impactful worldwide.

Breakup by End User:

Pediatrics

Adults

A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes pediatrics and adults.

Children, especially infants and toddlers, are highly vulnerable to pneumococcal infections, which can lead to serious illnesses, such as pneumonia, meningitis, and sepsis. Vaccination against pneumococcus bacteria is therefore recommended as part of routine childhood immunization schedules worldwide. The effectiveness of pneumococcal vaccines in preventing these infections is significantly reducing morbidity and mortality rates among children globally. Moreover, public health initiatives and immunization programs focused on pediatric populations are contributing to the pneumococcal vaccines market statistics.

As adults are aging, especially those over 65 or with underlying health conditions, they are becoming more vulnerable to pneumococcal infections, which can lead to serious illnesses, such as pneumonia, meningitis, and septicemia. Vaccination in adults helps reduce the risk of these infections and their associated complications, improving overall health outcomes and reducing healthcare costs. Additionally, adults often serve as carriers of pneumococcal bacteria, potentially spreading it to more vulnerable populations like children and the elderly people.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest pneumococcal vaccine market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for pneumococcal vaccine.

As per the content updated in 2023 on the website of Centers for Medicare & Medicaid Services, U.S. health care spending grew 4.1 percent in 2022, reaching $4.5 trillion or $13,493 per person. The increasing healthcare expenditure reflects a greater emphasis on improving patient outcomes and reducing overall healthcare costs through innovative technologies. Moreover, North America has stringent regulatory frameworks and strong government support for immunization programs that contribute significantly to the growth of the market. The prevalence of pneumococcal diseases in North America, coupled with increasing awareness among healthcare professionals and the general population about the benefits of vaccination, is also driving the demand for pneumococcal vaccines.

Competitive Landscape:

The market pneumococcal vaccine market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the pneumococcal vaccine industry include Astellas Pharma Inc., GlaxoSmithKline Plc., Merck & Co. Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt Ltd, and Walvax Biotechnology Co. Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Key players are investing in research and development (R&D) activities aimed at developing next-generation vaccine formulations. They are also expanding manufacturing capabilities to meet the growing global demand. Key players are also investing in clinical trials and studies to demonstrate efficacy and safety. They are also adopting innovative technologies for vaccine production and distribution. Many companies are implementing vaccination campaigns and educational programs to increase awareness and vaccine uptake. Key players are collaborating with other industry stakeholders, government agencies, healthcare organizations, and research institutions to expand their market reach and develop new products. For instance, in 2023, Vaxcyte, Inc. collaborated with Lonza for a new commercial manufacturing agreement. With this collaboration, Vaxcyte planned to expand its commercial manufacturing capacity for its PCV candidates.

Pneumococcal Vaccine Market Recent News:

January 26, 2024: Pfizer Inc. received marketing authorization from the Committee of Medicinal Products designed for Human Use (CHMP) of the European Medicines Agency (EMA) for its 20-valent pneumococcal conjugate vaccine candidate (20vPnC).

April 22, 2024: Takeda, Astellas and Sumitomo Mitsui Banking announced an agreement to establish a joint venture company for incubation of early drug discovery programs.

Key Questions Answered in This Report

  • 1. What was the size of the global pneumococcal vaccine market in 2023?
  • 2. What is the expected growth rate of the global pneumococcal vaccine market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global pneumococcal vaccine market?
  • 4. What are the key factors driving the global pneumococcal vaccine market?
  • 5. What is the breakup of the global pneumococcal vaccine market based on the vaccine type?
  • 6. What is the breakup of the global pneumococcal vaccine market based on the product type?
  • 7. What is the breakup of the global pneumococcal vaccine market based on the distribution channel?
  • 8. What are the key regions in the global pneumococcal vaccine market?
  • 9. Who are the key players/companies in the global pneumococcal vaccine market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pneumococcal Vaccine Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Pneumococcal Conjugate Vaccine
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Pneumococcal Polysaccharide Vaccine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Product Type

  • 7.1 Prevnar 13
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Synflorix
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Pneumovax 23
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Distribution Partner Companies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Non-Governmental Organizations (NGO)
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Government Authorities
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pediatrics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Adults
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Astellas Pharma Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 GlaxoSmithKline Plc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Merck & Co. Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Panacea Biotec Ltd.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Pfizer Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Sanofi S.A.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Serum Institute of India Pvt Ltd.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 Walvax Biotechnology Co. Ltd.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials

List of Figures

  • Figure 1: Global: Pneumococcal Vaccine Market: Major Drivers and Challenges
  • Figure 2: Global: Pneumococcal Vaccine Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Pneumococcal Vaccine Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Pneumococcal Vaccine Market: Breakup by Vaccine Type (in %), 2023
  • Figure 5: Global: Pneumococcal Vaccine Market: Breakup by Product Type (in %), 2023
  • Figure 6: Global: Pneumococcal Vaccine Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Pneumococcal Vaccine Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Pneumococcal Vaccine Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Pneumococcal Vaccine (Pneumococcal Conjugate Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Pneumococcal Vaccine (Pneumococcal Conjugate Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Pneumococcal Vaccine (Pneumococcal Polysaccharide Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Pneumococcal Vaccine (Pneumococcal Polysaccharide Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Pneumococcal Vaccine (Prevnar 13) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Pneumococcal Vaccine (Prevnar 13) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Pneumococcal Vaccine (Synflorix) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Pneumococcal Vaccine (Synflorix) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Pneumococcal Vaccine (Pneumovax 23) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Pneumococcal Vaccine (Pneumovax 23) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Pneumococcal Vaccine (Distribution Partner Companies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Pneumococcal Vaccine (Distribution Partner Companies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Pneumococcal Vaccine (Non-Governmental Organizations-NGO) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Pneumococcal Vaccine (Non-Governmental Organizations-NGO) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Pneumococcal Vaccine (Government Authorities) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Pneumococcal Vaccine (Government Authorities) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Pneumococcal Vaccine (Pediatrics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Pneumococcal Vaccine (Pediatrics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Pneumococcal Vaccine (Adults) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Pneumococcal Vaccine (Adults) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: North America: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: North America: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: United States: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: United States: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Canada: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Canada: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Asia-Pacific: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Asia-Pacific: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: China: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: China: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Japan: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Japan: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: India: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: India: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: South Korea: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: South Korea: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Australia: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Australia: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Indonesia: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Indonesia: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Others: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Others: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Europe: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Europe: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Germany: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Germany: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: France: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: France: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: United Kingdom: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: United Kingdom: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Italy: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Italy: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Spain: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Spain: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Russia: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Russia: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Others: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Others: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Latin America: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Latin America: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Brazil: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Brazil: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Mexico: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Mexico: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Others: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Others: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Middle East and Africa: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Middle East and Africa: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Middle East and Africa: Pneumococcal Vaccine Market: Breakup by Country (in %), 2023
  • Figure 78: Global: Pneumococcal Vaccine Industry: SWOT Analysis
  • Figure 79: Global: Pneumococcal Vaccine Industry: Value Chain Analysis
  • Figure 80: Global: Pneumococcal Vaccine Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pneumococcal Vaccine Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Pneumococcal Vaccine Market Forecast: Breakup by Vaccine Type (in Million US$), 2024-2032
  • Table 3: Global: Pneumococcal Vaccine Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
  • Table 4: Global: Pneumococcal Vaccine Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Pneumococcal Vaccine Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Pneumococcal Vaccine Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Pneumococcal Vaccine Market: Competitive Structure
  • Table 8: Global: Pneumococcal Vaccine Market: Key Players